中国批准为早期结肠癌、提高治愈率和减少化疗需求进行首次双重免疫疗法。 China approves first dual immunotherapy for early-stage colon cancer, boosting cure rates and reducing need for chemo.

中国国家医疗产品管理局批准了创新生物学TABOSUN(Pilimumab N01注射)与TYVYT(sintilimab)结合,对二B-III MSI-H/dMMMR结肠癌进行新发病治疗。 China's National Medical Products Administration has approved Innovent Biologics' TABOSUN® (ipilimumab N01 injection) combined with TYVYT® (sintilimab) for neoadjuvant treatment of resectable stage IIB-III MSI-H/dMMR colon cancer. 这种双重免疫性肿瘤疗法是全球批准用于这一用途的第一次和唯一的此类疗法,大大提高了病理学全面反应率。 This dual immune-oncology regimen is the first and only such therapy globally approved for this use, significantly improving pathological complete response rates. 这项核准为结肠癌子集提供了一个新的选择,该子集的化疗反应有限,有可能消除手术后化疗的需要,减少复发风险。 The approval offers a new option for a colon cancer subset with limited chemotherapy response, potentially eliminating the need for post-surgery chemotherapy and reducing recurrence risk.